ArticleFrontiers in public health2025
Dying to pay: end-of-life medical costs for middle-aged and older adult patients with cardiovascular and cerebrovascular diseases.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate end-of-life healthcare expenditures among middle-aged and older patients with cardiovascular and cerebrovascular diseases, with a particular focus on the existence of the "nearing-death effect." Methods: Using inpatient discharge summary data from the Chinese National Medical Insurance Settlement Platform, we identified a cohort of middle-aged and older adults (aged 45 and above) diagnosed with cardiovascular and cerebrovascular diseases in Province H, China, during 2018-2019. Propensity Score Matching (PSM) was employed to examine differences in end-of-life healthcare expenditures between deceased and surviving patients. Robustness checks were performed using Multidimensional Fixed Effects (MDFE) and Difference-in-Differences Machine Learning (DDML). Results: The findings reveal a substantial increase in end-of-life healthcare expenditures among patients with cardiovascular and cerebrovascular diseases. Specifically, Total Medical Costs, Comprehensive Service Fees, Diagnosis Fees, Treatment Fees, Pharmaceutical Fees, and Nursing Care Fees rose by 34.3, 44.0, 35.7, 62.5, 49.9, and 46.8%, respectively, all statistically significant at the 1% level. These results highlight a pronounced escalation in healthcare expenditures associated with patient mortality. Conclusion: Among middle-aged and older patients with cardiovascular and cerebrovascular diseases, healthcare expenditures exhibit a distinct "end-of-life effect," characterised by a sharp surge in medical spending during the final stages of life. This phenomenon underscores the intensive utilization of medical resources at the end of life, markedly differing from healthcare expenditure patterns at other stages of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.